Pamela Moussavou Boundzanga

Dr. Pamela Moussavou Boundzanga

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 January 2024 in Viruses
Verified
Journal Article
Open access
PDF file
Augustin MOUINGA ONDEMEAugustin MOUINGA ONDEME
Augustin MOUINGA ONDEME
LMLONGO PENDY Michel
LONGO PENDY Michel
IKIvan Cyr Moussadji Kinga
Ivan Cyr Moussadji Kinga
NBNgoubangoye Barthelemy
Ngoubangoye Barthelemy
PBPamela Moussavou Boundzanga
Pamela Moussavou Boundzanga
ENEdgard-Brice Ngoungou
Edgard-Brice Ngoungou
The Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome (HIV/AIDS) is still one of the main causes of death in sub-Saharan Africa. Antiretroviral therapies (ARTs) have significantly improved the health conditions of people living with HIV/AIDS (PLWHA). Consequently, a significant drop in morbidity and mortality, along with a reduced incidence of opportunistic infections (OIs), has been observed. However, certain atypical and biological profiles emerge in ART patients post-examination. The objective of this study was to identify the risk factors that contributed to the onset of OIs in HIV patients undergoing ART in Gabon. Epidemiological and biological data were obtained from medical records (2017 to 2019) found at the outpatient treatment centre (CTA) of Franceville in Gabon. Samples for blood count, CD4, and viral load analysis at CIRMF were collected from PLWHA suffering from other pathogen-induced conditions. A survey was carried out and data were analysed using Rstudio 4.0.2 and Excel 2007 software. Biological and socio-demographic characteristics were examined concerning OIs through both a univariate analysis via Fisher’s exact tests or chi2 (χ2), and a multivariate analysis via logistic regression. Out of the 300 participants initially selected, 223 were included in the study, including 154 (69.05%) women and 69 (30.95%) men. The mean age was 40 (38.6; 41.85), with individuals ranging from 2 to 77 years old. The study cohort was classified into five age groups (2 to 12, 20 to 29, 30 to 39, 40 to 49, and 50 to 77 years old), among which the groups aged 30 to 39 and 40 to 49 emerged as the largest, comprising 68 (30.5%) and 75 (33.6%) participants, respectively. It was noted that 57.9% of PLWHA had developed OIs and three subgroups were distinguished, with parasitic, viral, and bacterial infections present in 18%, 39.7%, and 55.4% of cases, respectively. There was a correlation between being male and having a low CD4 T-cell count and the onset of OIs. The study revealed a high overall prevalence of OIs, and extending the study to other regions of Gabon would yield a better understanding of the risk factors associated with the onset of these infections.

27 August 2022 in IJID Regions
Verified
Journal Article
Open access
BIBERTHE AMELIE IROUNGOU
BERTHE AMELIE IROUNGOU
PBPamela Moussavou Boundzanga
Pamela Moussavou Boundzanga
EEeric elguero
eric elguero
JMJamal Makran
Jamal Makran
BBBerthold Bivigou-Mboumba
Berthold Bivigou-Mboumba
Avelin F. AghokengAvelin F. Aghokeng
Avelin F. Aghokeng
To estimate the seroprevalence of anti-SARS-CoV-2 antibodies in the general population in Gabon, Central Africa. From May to July 2021, a cross-sectional study involving participants recruited in the general population in three districts in Gabon was conducted. Eligible participants who provided written informed consent were tested for anti-SARS-CoV-2 antibodies using a simple rapid diagnostic assay. Overall, 1609 participants were recruited, 1361 (84.6%) from urban sites and 248 (15.4%) from a rural area. The estimated overall seroprevalence was 13.1% (95% CI 11.4–14.8%). The risk of seropositivity increased with age, and the prevalence in the different age groups ranged from 12.9% (8.0–19.4%) in those aged 15–24 years to 23.3% (14.2–34.6%) in those ≥ 65 years old. A higher prevalence was found in the rural population (17.3%; 12.8–22.6%) compared with urban regions (12.3%; 10.6–14.1%). Being a woman was also associated with higher risk of infection (p < 0.001). This seroprevalence survey revealed a moderate seroprevalence in Gabon, illustrating a relatively low rate of circulation of the virus in the country and correlating with low numbers of confirmed cases and deaths reported to date.

Verified
Journal Article
Open access
PDF file
AMAnthony Idam Mamimandjiami
Anthony Idam Mamimandjiami
JEJéordy Dimitri Engone-Ondo
Jéordy Dimitri Engone-Ondo
PBPamela Moussavou Boundzanga
Pamela Moussavou Boundzanga
Augustin MOUINGA ONDEMEAugustin MOUINGA ONDEME
Augustin MOUINGA ONDEME
IMIvan S. Mfouo-Tynga
Ivan S. Mfouo-Tynga
Kaposi’s sarcoma (KS) is a tumor that primarily affects the skin, caused by a multifactorial pathogenesis mediated through immune dysfunction, often leading to increased morbidity and mortality in Sub-Saharan Africa (SSA). Human herpesvirus-8, also known as Kaposi’s sarcoma-associated herpesvirus (KSHV), induces an infection that can facilitate the pathogenesis of KS and other conditions. All KSHV subtypes depend on the expression of specific markers, such as K1 proteins, which play critical roles in their life cycles. The infection is unevenly scattered worldwide, with individuals infected with human immunodeficiency virus (HIV) and pregnant women being among the most vulnerable groups. HIV infection and related effectors, such as TAT proteins, have substantial impacts on KSHV infectiousness, angiogenesis, various signaling pathways, and KS pathogenesis. Africa endures the heaviest burden of KS, which affects both men and women, sometimes from an early age. KS’s pathogenesis and underlying mechanisms remain unclear; this study aims to highlight the dynamics to be considered in managing and mitigating the burden of KS in SSA. In that region, certain infections are endemic and can cause intermediate health damage leading to KS tumorigenesis, highlighting the link between non-communicable and communicable diseases.

14 August 2025 in Diseases
Verified
Journal Article
Open access
PDF file
MMMarcelle MBOUMBA-MBOUMBA
Marcelle MBOUMBA-MBOUMBA
Augustin MOUINGA ONDEMEAugustin MOUINGA ONDEME
Augustin MOUINGA ONDEME
PBPamela Moussavou Boundzanga
Pamela Moussavou Boundzanga
JEJéordy Dimitri Engone-Ondo
Jéordy Dimitri Engone-Ondo
RMRoseanne Mounanga Mourimarodi
Roseanne Mounanga Mourimarodi
IMIvan S. Mfouo-Tynga
Ivan S. Mfouo-Tynga
Background/Objectives. Women living with human immunodeficiency virus (WLWH) have a six-fold higher risk of developing cervical cancer associated with high-risk human Papillomavirus (HR-HPV) than HIV-negative women. We herein assessed HR-HPV genotype distribution and plasma levels of the cancer antigen 125 (CA-125) in WLWH in a rural town in Gabon, in Central Africa. Methods. Adult WLWH attending the local HIV outpatient center were prospectively enrolled and underwent cervical visual inspection and cervicovaginal and blood sampling. HIV RNA load and CA-125 levels were measured from plasma using the Cepheid® Xpert® HIV-1 Viral Load kit and BioMérieux VIDAS® CA-125 II assay, respectively. HPV detection and genotyping were performed via a nested polymerase chain reaction (MY09/11 and GP5+/6+), followed by sequencing. Results. Fifty-eight WLWH (median age: 52 years) were enrolled. Median CD4 count was 547 cells/µL (IQR: 412.5–737.5) and HIV RNA load 4.88 Log10 copies/mL (IQR: 3.79–5.49). HPV prevalence was 68.96%, with HR-HPV detected in 41.37% of women. Among HR-HPV-positive samples, 87.5% (21/24) were genotypes targeted by the Gardasil vaccine, while 12.5% (3/24) were non-vaccine types. Predominant HR-HPV types included HPV-16 (13.8%), HPV-33 (10.34%), HPV-35 (5.17%), HPV-31, and HPV-58 (3.45%). Most participants had normal cervical cytology (62.07%), and a minority (14.29%) had elevated CA-125 levels, with no correlation to cytological abnormalities. Conclusions. In the hinterland of Gabon, WLWH are facing an unsuspected yet substantial burden of cervical HR-HPV infection and a neglected risk for cervical cancer. Strengthening cervical cancer prevention through targeted HPV vaccination, sexual education, and accessible screening strategies will help in mitigating associated risk.

15 September 2022 in Frontiers in Oncology
Verified
Journal Article
Open access
PBPamela Moussavou Boundzanga
Pamela Moussavou Boundzanga
PBPatrice Emery Itoudi Bignoumba
Patrice Emery Itoudi Bignoumba
AMAugustin Mouinga-Ondeme
Augustin Mouinga-Ondeme
BIBerthe Amelie Iroungou
Berthe Amelie Iroungou
BBBerthold Bivigou-Mboumba
Berthold Bivigou-Mboumba
Pascal PineauPascal Pineau
Pascal Pineau
Chronic liver diseases still represent a worrying public health issue in Sub-Saharan Africa. In this region, emphasis is generally made on hepatocellular carcinoma (HCC) albeit liver cirrhosis (LC) is also responsible for an important death toll. Very few studies have compared the presentation and etiologies of cancer and cirrhosis of the liver in Middle Africa. We conducted a comparative retrospective analysis of 74 and 134 cases of patients with HCC and LC treated in Libreville, Gabon. Viral or lifestyle risk factors, clinical symptoms, and biological features were compared. We observed that ages of diagnosis were 53.2 ± 15.7 years and 48.6 ± 18.6 years for HCC and LC with remarkably low M:F sex ratios (1.3–1.8). Ethanol consumption was highly prevalent in both disease types (65.0%–70.0%). Chronic viral infections with hepatitis B (HBV) or C (HCV) virus were also widespread with slight domination of the former in both diseases (43.4% vs. 34.3%, and 35.9% vs. 28.5%). Patients with HCC were presenting very late with a mean diameter of the main nodule of 84 ± 50 mm and a multifocal pattern in 72.7% of cases. HCC developed on a cirrhotic liver in 91.7% of cases. Serum AFP was frankly elevated (>400 ng/ml) in only 35.8% of HCC cases. The most striking feature of the HCC series was the contrasted contribution of distinct pathogenic etiologies involving sex, viral, metabolic, and toxic factors. A frequently dysmetabolic condition synergizing with hepatitis C (anti-HCV, 73.8% vs 22.7%, p < 0.0001) in females and a male cancer promoted by recreational toxicants and chronic hepatitis B (HBsAg, 83.5% vs 35.9%, p < 0.0001) were observed. Men with HCC were considerably younger than women (46.8 ± 14.5 years vs. 62.2 ± 12.2 years, p < 0.0001). Further studies are now warranted to identify routes of HCV transmission and if they are still fueling reservoirs of future patients. Public policies to prevent alcohol-related harm have also to be urgently implemented in Gabon.

27 April 2022 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
JEJéordy D Engone-Ondo
Jéordy D Engone-Ondo
MBMichelle Bignoumba
Michelle Bignoumba
PBPamela Moussavou Boundzanga
Pamela Moussavou Boundzanga
AGAmahani Gafou
Amahani Gafou
ADAbdoulaye Diane
Abdoulaye Diane
Avelin F. AghokengAvelin F. Aghokeng
Avelin F. Aghokeng